Kornimate/medical-research-clean huggingface dataset:
clinical investigation of syndi

Conditions: Mental Health Issue; Depression; Anxiety

Summary: mental health concerns are a growing global concern, but support can still be difficult to access. digital health technologies can help people access support, but with over 10,000 mental health apps available, it can be difficult to choose one that is safe, effective, and personalised. syndi is a digital health platform that uses a machine learning system to provide personalised recommendations of mental health apps. this study aims to examine the impact of syndi and its recommendations on the mental health and well-being of people with mental health concerns. the investigators will use the standard national health service (nhs) talking therapies measures of anxiety and depression, as well as additional measures of wellbeing and functional impairment to look at the impact of syndi on patients' mental well-being. the investigators will also look at user experience with syndi using a survey. users' engagement with syndi and its recommended apps will be assessed using a short survey and some participants will be randomly selected for an interview so the investigators can get a better understanding of what people liked and disliked about using the platform and why. the investigators expect that the project will show that using syndi helps improve mental well-being in people with mental health concerns. if the study shows this positive impact, this will provide evidence to support the use of syndi to improve the accessibility of mental health support in clinical pathways. the investigators will publish the results of the study in academic journals as well as in more accessible platforms.


Eligibility criteria:
inclusion criteria: * based in the uk * referred or self-referred to proceed through the standard nhs talking therapies care pathway or people with mental health concerns looking for app recommendations online; * willing and able to provide informed consent; * aged 18 years or older; * able to speak english; * have access to the internet and own a smartphone. exclusion criteria: * patients with a phq-9 score \>=20 * patients with suicidal ideation measured as an answer of 'yes' to any question in the columbia suicide severity rating scale (c-ssrs); * incapable of self-consent; * in a dependent/unequal relationship with the research or care teams or any ppi representatives.

Keywords: digital health recommender system mental health telemedicine
optiflow vs. convential anesthesia during pediatric laryngeal papilloma removal

Conditions: Laryngeal Papilloma, Recurrent

Summary: this is a randomized cross over study of high flow oxygen delivery via nasal cannula vs. conventional tubeless anesthesia for patients undergoing dubulking surgery for laryngeal papilloma. ten patients aged 2-17 with laryngeal papilloma that are eligible for debulking surgery will be consented and enrolled.

this trial will be a randomized unmasked open-label study of transnasal humidified high-flow oxygen/air delivery compared to conventional tubeless anesthesia during airway surgery in pediatric patients. this will be a single center study at mee main campus on 243 charles st, boston, ma for the use of the high-flow oxygen delivery device. two study arms will be used in this study. subjects will be treated with both study arms over the course of two study visits. enrolled patients will be patients that present themselves routinely for removal of laryngeal papilloma. these patients, once enrolled, will be randomized to either receive conventional tubeless anesthesia or standard anesthesia with the addition of transnasal high-flow oxygen/air for their next scheduled anesthetic. oxygen flows for the high-flow nasal cannula will be titrated down to achieve a fio2 value of 21% during lasering. the anesthesia method not chosen will be used for the following anesthetic for each patient. intraoperatively patients will be monitored for number of desaturations below 90 percent, length of these desaturations and severity, number and type of interventions necessary by the anesthesiologist, and number of intubations necessary by the anesthesiologist. flow rates appropriate for the age of the patient will be used and also be recorded within these cases. adverse events and complications will also be recorded for both anesthetics.

Eligibility criteria:
inclusion criteria: 1. diagnosis of laryngeal papilloma via endoscopic exam by a pediatric ent surgeon. and the expectation that he or she will require multiple debulking surgeries. 2. age 2-17 years old at time of consent and both surgeries. 3. parent/guardian consent and patient assent has been given. exclusion criteria: 1. patients with nasal obstructions or are otherwise not candidates for high flow oxygen delivery via nasal cannula. 2. patients with underlying complicating pulmonary diseases like severe asthma, pulmonary hypertension, or ongoing pneumonia. 3. pregnant patients. 4. absence of parent or legal guardian able to provide written consent. 5. patients who in the opinion of the investigator would not be good candidates for debulking surgery.
local anesthetic for plateau fractures

Conditions: Tibial Plateau Fractures

Summary: subjects may receive an injection at the end of the surgery to fix their broken leg that may reduce their pain and hospital stay

subjects will be randomized to bupivicaine or saline injection in the joint at the end of open reduction internal fixation of the tibial plateau fracture

Eligibility criteria:
inclusion criteria: * age \>=18 year , * tibial plateau fracture undergoing open reduction and fixation" exclusion: * allergy to bupivacaine * prolonged external fixator use

Keywords: tibial plateau fracture
the changes of patterns of microarray in patients with obstructive sleep apnea

Conditions: Sleep Apnea, Obstructive

Summary: the aim of this study are (1) to genome-wide profile the gene expression patterns of peripheral blood mononuclear cell (pbmc) in patients with obstructive sleep apnea (osa) (2) to profile the gene expression patterns change before and after treatment with continuous positive airway pressure (cpap) (3) to correlate the altered gene expression with the severity of the disease and outcome of osa patients

obstructive sleep apnea syndrome (osas) is characterized with recurrent collapse of upper airway during sleep and resulted in hypoxia and sleep fragmentation. several systemic and cardiovascular complications have been attributed to osas, which is caused by hypoxia and bursts of sympathetic activity. increase of inflammatory mediators, which included c-reactive protein, oxidative stress, adhesion molecules, vascular endothelial growth factor and proinflammatory cytokines, were thought to involve in the developments of cardiovascular diseases in patients with osas. in our preliminary study, both serum levels of il-6 and crp were higher in patients with osas than control subjects, and the levels were inversely correlated with the lowest pulse oxygen saturation. factors triggering inflammatory cascades in osas included hypoxia and sympathetic hyperactivity. hypoxia was thought to be the trigger factor for the elevated production of inflammatory mediators. through the induction of transcriptional factors and critical signaling pathways, hypoxia induces several physiologic responses, like increased anaerobic metabolism, angiogenesis, vasodilation, erythropoiesis and increased breathing. microarray is the more mature gene analysis techniques so far, which can allow high throughput analysis of the function of many genes. microarray can be used to understand the disease mechanisms and is also very useful to improve disease diagnosis, disease classification, prognosis evaluation and to improve treatment outcome. in this project, we use oligo microarray to genome-wide profile the altered gene expressions in peripheral blood mononuclear cells of osas patients; and to correlate the dysregulations of gene expression with the clinical outcome. we will also examine the gene expression patterns change before and after treatment with cpap. the information obtained by this approach will be very useful to understand the pathogenic mechanism of osas that leads to the systemic and cardiovascular complications. further therapeutic intervention may therefore be possible.

Eligibility criteria:
inclusion criteria: * healthy control with age \> 18 y/o severe osa (ahi\>=30/hr) with age\>18 y/o exclusion criteria: * chronic lung disease female refuse to receive cpap treatment or poor compliant to cpap neurologic event

Keywords: sleep apnea continuous positive airway pressure microarray polysomnography
a study of dostarlimab in participants with untreated locally advanced rectal cancer in china

Conditions: Neoplasms, Rectal

Summary: the main goal of this study is to evaluate the effect of dostarlimab monotherapy in chinese participants with locally advanced mismatch-repair deficient (dmmr)/ microsatellite instability-high (msi-h) rectal cancer who have received no prior treatment.


Eligibility criteria:
inclusion criteria: * participant has histologically confirmed stage ii to iii (t3-t4, n0, or t any, n+), locally advanced rectal adenocarcinoma * participant has radiologically and endoscopically evaluable disease * participant has a tumor which can be categorized as dmmr or msi-h by central assessment exclusion criteria: * participant has distant metastatic disease * participant has received prior radiation therapy, systemic therapy, or surgery for management of rectal cancer * has a known additional malignancy that progressed or required active treatment within the past 2 years * has an active autoimmune disease that has required systemic treatment in the past 2 years * has experienced any of the following with prior immunotherapy: any irae ≥ grade 3, immune-related severe neurologic events of any-grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, guillain barré syndrome, or transverse myelitis), exfoliative dermatitis of any grade \[sjs (stevens-johnson syndrome, ten (toxic epidermal necrolysis), dress (drug rash with eosinophilia and systemic symptoms)\], or myocarditis of any grade. non-clinically significant laboratory abnormalities are not exclusionary * has any history of interstitial lung disease or pneumonitis * has received or plans to receive an organ or stem cell transplant that uses donor stem cells (allogeneic stem cell transplant) * has a history of severe allergic and/or anaphylactic reactions to chimeric, human, or humanized antibodies, fusion proteins, or known allergies to dostarlimab, or its excipients

Keywords: dostarlimab gsk4057190a tsr-042 rectal cancer dmmr msi-h
impact of three-dimensional visualization on operation strategy and complications for hilar cholangiocarcinoma

Conditions: Hilar Cholangiocarcinoma

Summary: the aim of the multi-centre study is to evaluate correctly the impact of three-dimensional visualization on operation strategy and complications for hilar cholangiocarcinoma.

because of the complexity of hilar cholangiocarcinoma,the limitations of 2d images of ct/mri and the uncertainty of surgeons'experience, it is difficult for the surgeons to diagnosis and assess the operation strategy accurately based on traditional 2d imaging(ct/mri).the aim of the multi-centre study is to evaluate correctly the impact of three-dimensional visualization on operation strategy and complications for hilar cholangiocarcinoma.

Eligibility criteria:
inclusion criteria: 1. 18 years≤ age ≤70 years 2. complying with the diagnosis criteria of hilar cholangiocarcinoma. 3. without intrahepatic or extrahepatic extensive cancer metastasis. 4. preoperative serum bilirubin ≤51.3 umol/l or preoperative serum bilirubin \< 200 umol/l after the drainage by ptcd(percutaneous transhepaticcholangial drainage)/enbd(endoscopic nasobiliary drainage). 5. the patients are volunteered for the study. exclusion criteria: 1. patients with mental illness. 2. patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.) 3. the patients refused to take part in the study. 4. there are other co-existed malignant tumors.

Keywords: three dimensional visualization operation strategy
effects of oxytocin on behavior and physiology in a psychotherapy setting

Conditions: Behavior; Anxiety

Summary: subjects-currently in outpatient mental health care--will participate in 2 psychotherapy sessions, one with oxytocin spray and one with placebo spray. sessions will be videotaped, and cortisol and heart rate will be measured. we hypothesize that oxytocin will have positive benefits on nonverbal behavior in the therapy session, as well as have positive effects on subjective anxiety, cortisol and heart rate.


Eligibility criteria:
inclusion criteria: * in current mental health treatment * male 18-65 exclusion criteria: * diagnosis of schizophrenia or psychosis * diagnosis of autism or aspergers disorder * active substance use disorder * at moderate or high risk of self-harm

Keywords: psychotherapy
bi 811283 in combination with cytarabine in previously untreated aml ineligible for intensive treatment

Conditions: Leukemia, Myeloid, Acute

Summary: investigation of maximum tolerated dose, safety, efficacy and pharmcokinetics of bi 811283 in combination with cytarabine (ld-ara-c) in previously untreated acute myeloid leukaemia (aml) patients


Eligibility criteria:
inclusion criteria: * male or female adult with previously untreated acute myeloid leukaemia (aml) * confirmed diagnosis of aml according to the who definition (except for acute promyelocytic leukaemia, apl) * patient is considered ineligible for intensive treatment * patient is eligible for low-dose cytarabine (ld-ara-c) treatment * life expectancy \> 3 months * eastern co-operative oncology group (ecog, r01-0787) performance score \<=2 at screening * signed written informed consent consistent with international conference on harmonisation good clinical practice (ich-gcp) and local legislation exclusion criteria: * patient with apl (aml subtype m3 according to the french-american-british (fab) classification). * relapsed or treatment refractory aml. * hypersensitivity to one of the trial drugs or the excipients. * other malignancy requiring treatment. * known central nervous system involvement. * aspartate amino transferase (ast) or alanine amino transferase (alt) greater than 2.5 times the upper limit of normal (uln). * inr \> 1.5 x uln for subjects not on therapeutic vitamin k antagonists (phenprocoumon, warfarin). * bilirubin greater than 1.5 mg/dl. * serum creatinine greater than 2.0 mg/dl. * lvef (left ventricular ejection fraction) \< 50% in echocardiography or clinical congestive heart failure new york heart association (nyha) grade iii or iv. * concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris or cardiac arrhythmia. * psychiatric illness or social situation that would limit compliance with trial requirements. * concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug (i.e. other chemo- or immunotherapy, see also section 4.2.2). * contraindications for cytarabine treatment according to the summary of product characteristics (spc). * patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial (hormonal contraception, intrauterine device, condom with spermicide, etc.). * pregnant or nursing female patients. * patient unable to comply with the protocol.
survey study about endoscopy during covid-19 pandemic for ibd doctors

Conditions: Inflammatory Bowel Diseases

Summary: performance of diagnostic or therapeutic endoscopic procedures in inflammatory bowel disease (ibd) patients can be challenging during a viral pandemic; the main concerns being the safety and protection of patients and health care providers (hcp). the aim of this study is to identify endoscopic practice patterns and outcomes of ibd and coronavirus disease 19 (covid-19) with a worldwide survey of hcp.

the 20-item survey questionnaire was sent to physician members of the american society for gastrointestinal endoscopy special interest group in interventional ibd, chinese ibd society endoscopy interest group, and the china crohn's and colitis foundation. the data of the survey was collected and analyzed.

Eligibility criteria:
inclusion criteria: 1. doctors who are involved in the endoscopic treatment of ibd patients; 2. the endoscopist reads and signs an informed consent online. - exclusion criteria: 1. doctors who are not involved in the endoscopic treatment of ibd patients 2. doctors who need the help of an agent, a witness, or someone else who can not complete the questionnaire independently. 3. other conditions that the researchers considered unsuitable for inclusion or influenced the participants'ability to complete the study.-
arterio-venous fistula audit. successful utilisation rates of arterio-venous fistulae for haemodialysis at university hospital limerick

Conditions: Arterio-venous Fistula

Summary: we wish to examine arterio-venous fistula (avf) and arterio-venous graft (avg) utilisation rates for haemodialysis at university hospital limerick. we want to determine out of the avf's that are surgically created, how many go on to be used as anticipated for haemodialysis treatments successfully.

there are over 2 million end-stage renal disease (esrd) patients who require renal replacement therapy worldwide, and this is estimated to rise to over 5 million by 2030 (liyanage et al. 2015). haemodialysis, used by the majority of esrd patients, requires vascular access, where blood can be taken out of the body (via cannulation) and pumped through an external dialysis machine, which filters the blood of waste and excess fluid before being returned. arterio-venous fistula creation is the preferred vascular access for haemodialysis, but has a large failure rate in the maturation period (colley et al. 2022). failure is usually attributed to insufficient dilation of the vessel and/or stenosis, which results in inadequate blood flow rates for the purpose of haemodialysis (dixon, 2006). the purpose of this audit is to examine over a three year period how many of the individuals who had an avf created are utilising it successfully for the purpose of haemodialysis as planned.

Eligibility criteria:
inclusion criteria: * patients who had an avf or avg surgically created over the last three years at uhl who are undergoing haemodialysis treatments are suitable for inclusion. * dates for audit purposes are 1st april 2019 to 1st april 2022. exclusion criteria: * patients outside of these set dates will be excluded. * patients who are not currently undergoing haemodialysis treatments are excluded.
post marketing surveillance to observe safety and efficacy of enbrel in pediatric patients with psoriasis

Conditions: Pediatric Psoriasis

Summary: enbrel was first approved as new medicine on 06 oct 2003 in korea and the indication of pediatric psoriasis was approved on 23 sep 2009. however, as required for any new indication approved by korea food and drug administration (kfda), safety and efficacy information of new indication should be provided at minimum 600 subjects administered in the setting of routine practice during the initial 4 years after new indication approved.

all patients enrolled should meet the usual prescribing criteria for enbrel in psoriasis as per the local product information for usage.

Eligibility criteria:
inclusion criteria: 1. children and adolescents aged 8 years to 17 years at time of consent 2. chronic severe psoriasis patients who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies exclusion criteria: 1. patients with known hypersensitivity to enbrel or any component of the product 2. patients with active infections including chronic or localized infections such as tuberculosis (treatment of enbrel should not be initiated)

Keywords: pediatric psoriasis enbrel safety efficacy
acupuncture with press tack needles for perioperative pain after open radical prostatectomy

Conditions: Prostate Cancer; Perioperative Pain

Summary: acupuncture has been shown in several meta-analyses and clinical studies, in different surgical settings and chronic back pain, to be a safe adjuvant option for postoperative pain treatment. in this study, the investigator hypothesize that acupuncture can decrease postoperative pain intensity and amount of given analgesics, and accelerate recovery of bowel motility, in patients after open radical prostatectomy. the investigator will also investigate whether or not acupuncture with needle skin penetration is more efficacious than acupressure.

this study will be a randomized, controlled and partially blinded study with three arms: 1) press tack needle acupuncture (acu) and routine postoperative analgesic care, 2) press tack placebo acupressure (sham) and routine postoperative analgesic care, and 3) only routine postoperative analgesic care (control).

Eligibility criteria:
inclusion criteria: * males aged 18-70 years * diagnosis with prostate cancer and scheduled for open radical prostatectomy * ability and willingness to follow study instructions and complete all required questionnaires during hospitalization and follow-up * written informed consent exclusion criteria: * inability to understand the terms of this study * simultanously participation in other clinical trials possibly influencing primary or secondary endpoints or any acupuncture-related clinical trials within 30 days prior to inclusion * prior surgery within the last three months * received acupuncture within 6 weeks before surgery * known hypersensitivity or fear of acupuncture * known abuse of drugs, medications and alcohol * chronic pain for more than 3 months * continuous opioid analgesic medications for more than 3 days during the 4 weeks prior to surgery

Keywords: prostate cancer pain management acupuncture acupressure
the effect of coleus forskohlii extract on the risk factors of metabolic syndrome

Conditions: Metabolic Syndrome; Obesity

Summary: coleus forskohlii extract contains the bioactive compound, forskolin. preliminary studies have shown that forskolin can increase fat metabolism thus reduce fat accumulation in both animals and humans. it has been suggested that forskolin may also suppress appetite thus reduce energy intake and results in weight loss. this study will evaluate the appetite suppressant properties of coleus forskohlii extract. in addition the effect on central obesity and risk factors of metabolic syndrome will also be investigated.


Eligibility criteria:
inclusion criteria: * both australian males and females, age 20-60 years, overweight or obese (bmi \>25), waist circumference of \> 94 cm (male), waist circumference of \>80 cm (female) exclusion criteria: * cigarette smoker, hypertension, all types of heart, liver and kidney disease, pregnancy, lactating, type 1 diabetes and weight loss medication.

Keywords: obesity herbal remedies metabolic disorders